Floatz logo

Benzeneethanamine, N-Ethyl-?-Methyl-4-(Trifluoromethyl)-, Hydrochloride, (±)-

Lennox-Gastaut Syndrome

University of ChicagoSmall moleculePhase 3Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Lennox-Gastaut Syndrome cohort.

Asset / SponsorPhaseRating
gwp42003-p
Jazz Pharmaceuticals
Phase 4BBB
Rufinamide
Eisai Co., Ltd.
Phase 3BB
zx008
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Phase 3BB
Bexicaserin
Longboard Pharmaceuticals
Phase 2BB
MELATONIN
Institution de Lavigny
Phase 4BB

View all 12 →

Same molecule, other indications

Benzeneethanamine, N-Ethyl-?-Methyl-4-(Trifluoromethyl)-, Hydrochloride, (±)- is also rated in:

Dravet syndromeActive
BBB
Indicative · Phase 4
78 / 100
View asset →
cognitive disorderDormant
BB
Indicative · Phase 4
69 / 100
View asset →
infantile spasmsActive
BB
Indicative · Phase 3
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →